ArticleFrontiers in endocrinology2026
Osteogenesis imperfecta: a registry-based study of the clinical symptoms of disease in a large cohort of Italian patients.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Osteogenesis imperfecta (OI) is a rare, heritable, skeletal disorder resulting in defective bone formation. Clinical presentation is heterogeneous. This study aims to provide an overview of the clinical manifestations by disease severity and age in a large cohort of Italian patients with OI. Methods: Patients with OI who received care at the IRCCS Istituto Ortopedico Rizzoli from 2005 to 2024 were enrolled in the Registry of Osteogenesis Imperfecta database and analyzed for this study. Results: Overall, 628 patients with OI were included in the study (51.1% had Type I, 5.1% Type III, 6.7% Type IV, 0.3% Type V, and 36.8% unknown type). Patient height was reduced with increasing disease severity (Type I had mildly reduced height and Type III had marked height reduction). Fractures were common across all OI groups. The annualized fracture rates were highest in younger patients (288.31 per 1,000 person years) and patients with Type III, Type IV OI and unknown type. Skeletal deformities were present across all OI types and in every age group, with trunk deformities being most frequently reported. An estimated 10-30% of all patients suffered from functional limitations. Extraskeletal manifestations (skin abnormalities, hearing loss, valvulopathies, scleral discoloration, joint hyperlaxity, and dental abnormalities) were common. Conclusion: Various parameters including height, weight, fractures, and skeletal and extraskeletal deformities vary by OI type and patient age. These findings support the need for phenotype-informed, life-course care planning with the need for adaptations for age-related patterns to optimize patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.